P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

• A. Russell-Smith,
• R. Shah,
• A. Silverstein,
• A. Petrilla,
• B. Leinwand,
• D. Norris,
• A. Schroeder

Affiliations

A. Russell-Smith

1 Pfizer R&D UK Ltd, Sandwich, United Kingdom

R. Shah

2 Pfizer Inc., New York

A. Silverstein

3 Inovalon

A. Petrilla

3 Inovalon

B. Leinwand

3 Inovalon

D. Norris

3 Inovalon

A. Schroeder

4 Avalere Health, Washington, United States of America